Sandostatin therapy in sarcoidosis

• Conditions: Sarcoidosis; MedDRA version: 16.1Level: HLGTClassification code 10003816Term: Autoimmune disordersSystem Organ Class: 10021428 - Immune system disorders; Therapeutic area: Diseases [C] - Immune System Diseases [C20]

• Registration Number: EUCTR2013-005376-17-NL
• Lead Sponsor: Erasmus Medical Center

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Start: 2014-02-27
• Last Update Posted: 14 March 2016

Recruitment & Eligibility

• Status: ot Recruiting
• Sex: All
• Target Recruitment: Not specified

Inclusion Criteria

•Age above 18 years with obtained written consent
•Have biopsy-proven symptomatic, stable, chronic sarcoidosis for minimal three years.
•Have a positive SRS
•Involvement of skin, joint, lymph nodes or lung. Patients with pulmonary involvement have a diffusing capacity between 60 and 75 percent.

Are the trial subjects under 18? no
Number of subjects for this age range:
F.1.2 Adults (18-64 years) yes
F.1.2.1 Number of subjects for this age range 20
F.1.3 Elderly (>=65 years) no
F.1.3.1 Number of subjects for this age range

Exclusion Criteria

•Corticosteroid use up to three months prior of trial
•Chronic renal failure defined as a GFR below 50%
•Liver disease
•Have an indication for intensifying immunosuppressive therapy; threatening organ damage
•Have received anti TNF-a therapy
•Have an underlying cardiac disease

Study & Design

• Study Type: Interventional clinical trial of medicinal product
• Study Design: Not specified